Drug intelligence / Profile preview

QLC1401

Development stage: Phase 2
Lead developer: Qilu Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

QLC1401 is an orally administered small molecule under clinical investigation as a treatment for **ER-positive, HER2-negative locally advanced or metastatic breast cancer**. It is being evaluated in combination with CDK4/6 inhibitors or mTOR inhibitors to assess its safety, tolerability, efficacy, and pharmacokinetics. The drug is currently being tested in a multicenter, open-label Phase Ib/II trial, which includes both dose escalation and dose expansion components[1][9].

Other names: QLC1401QLC-1401QLC 1401

Beyond the preview

Go deeper on QLC1401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QLC1401.

Explore the full profile